0000000001102480

AUTHOR

Cédric Langhi

0000-0002-7732-3882

showing 1 related works from this author

Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.

2013

PCSK9 (proprotein convertase subtilisin kexin type 9) is a secreted protease that modulates cholesterol homeostasis by decreasing low-density lipoprotein receptor expression. Low levels of plasma lipoproteins are related to severity of illness and survival in patients of intensive care units (ICU).The aim of the study was to investigate the regulation of plasma PCSK9 and its association with plasma lipid parameters and clinical markers of severity during critical illness.The plasma biobank from the previously published HYPOLYTE prospective study was used to measure PCSK9 concentrations by ELISA at days 0 and 8 in 111 patients admitted to surgical ICU for severe multiple trauma. Patients wer…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismReceptor expressionCritical IllnessClinical BiochemistryContext (language use)PlaceboBiochemistryGastroenterologySeverity of Illness IndexPlacebosEndocrinologyIntensive careInternal medicineSeverity of illnessmedicineHumansProspective cohort studyInfusion PumpsHydrocortisoneTrauma Severity Indicesbusiness.industryPCSK9Biochemistry (medical)Serine EndopeptidasesCholesterol LDLPrognosisIntensive Care UnitsEndocrinologyImmunologyWounds and InjuriesFemaleProprotein ConvertasesProprotein Convertase 9businessBiomarkersmedicine.drugThe Journal of clinical endocrinology and metabolism
researchProduct